Q1 Earnings Forecast for BDX Issued By William Blair

Becton, Dickinson and Company (NYSE:BDX) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research report issued on Thursday, February 6th. William Blair analyst A. Brackmann anticipates that the medical instruments supplier will post earnings of $3.34 per share for the quarter. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.41 per share. William Blair also issued estimates for Becton, Dickinson and Company’s Q2 2026 earnings at $3.81 EPS, Q3 2026 earnings at $4.04 EPS and Q4 2026 earnings at $4.50 EPS.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%.

BDX has been the topic of a number of other research reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler upped their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Up 1.3 %

Shares of NYSE:BDX opened at $230.22 on Friday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a market cap of $66.77 billion, a PE ratio of 38.76, a P/E/G ratio of 1.80 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock’s 50-day moving average is $231.90 and its 200 day moving average is $234.05.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB increased its stake in shares of Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after purchasing an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $767,000. Busey Bank increased its stake in shares of Becton, Dickinson and Company by 3.8% in the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.